World’s First Cannabis Chromosome Map Reveals the Plant’s Evolutionary History
The herb’s past points to its future as a potential medicine
Tetrahydrocannabinol (THC) and cannabidiol (CBD), bioactive substances produced by cannabis and sought by medical patients and recreational users, were created thanks to ancient colonization of the plant’s genome by viruses, which researchers at the Icahn School of Medicine at Mount Sinai and the University of Toronto report that they have identified for the first time.
The finding is only one of many insights revealed by the long-awaited cannabis genome map detailing gene arrangement on the chromosomes, published November 8, 2018, in the journal Genome Research. Among other revelations are discovery of a gene responsible for the production of cannabichromene (CBC), a lesser-known cannabinoid, and new insights into how the potency of a particular strain is determined.
“The chromosome map is an important foundational resource for further research which, despite cannabis’ widespread use, has lagged behind other crops due to restrictive legislation,” says Tim Hughes, PhD, a professor in the Donnelly Centre for Cellular and Biomolecular Research and co-leader of the study. Dr. Hughes is also a professor in the Department of Molecular Genetics and Senior Fellow at the Canadian Institute for Advancement of Research.
The researchers expect the map will speed up breeding efforts to create new strains with desired medical properties as well as varieties that can be grown more sustainably, or with increased resistance to diseases and pests.
The study was a three-part collaboration between Dr. Hughes’ team and those of Jonathan Page, PhD, of Aurora Cannabis and the University of British Columbia, and Harm van Bakel, PhD, of the Icahn School of Medicine at Mount Sinai in New York.
Drs. Hughes, Page, and van Bakel first got together in 2011 when they released the first draft of the cannabis genome, which was too fragmented to reveal gene position on chromosomes at the time.
The new map reveals how hemp and marijuana, which belong to the same species Cannabis sativa, evolved as separate strains with distinct chemical properties. Cannabis plants grown for drug use (“marijuana”) are abundant in psychoactive tetrahydrocannabinol, or THC, whereas hemp produces cannabidiol, or CBD, popular of late for its medicinal potential. Some people use CBD to relieve pain and it is also being tested as a treatment for epilepsy, schizophrenia, and Alzheimer’s disease.
The enzymes making THC and CBD are encoded by THCA and CBDA synthase genes, respectively. Both are found on chromosome 6 of the 10 chromosomes the cannabis genome is packaged into. There, the enzyme genes are surrounded by vast swathes of garbled DNA which came from virus-like elements that colonized the genome millions of years ago. These retroelements, made copies of itself that spread across the genome by jumping into other sites in the host cell’s DNA.
“Plant genomes can contain millions of retroelement copies,” says Dr. van Bakel, Assistant Professor of Genetics and Genomic Sciences and faculty member of the Icahn Institute for Data Science and Genomic Technology at the Icahn School of Medicine at Mount Sinai. “This means that linking genes on chromosomes is analogous to assembling a huge puzzle where three-quarters of the pieces are nearly the same color. The combination of a genetic map and PacBio sequencing technology allowed us to increase the size of the puzzle pieces and find enough distinguishing features to facilitate the assembly process and pinpoint the synthase genes.”
The researchers believe that gene duplication of the ancestral synthase gene and expanding retroelements drove ancient cannabis to split into chemically distinct types. Humans subsequently selected for plants containing desirable chemistry such as high THC.
The gene sequences for the THCA and CBDA synthases are nearly identical, supporting the idea that they come from the same gene which was duplicated millions of years ago. Over time, each gene copy evolved separately, and eventually came to encode the two different enzymes that produce the distinct cannabinoids.
Because the genes encoding enzymes are so similar at the DNA level, prior to this study it was not clear whether they were encoded by separate genes or by two versions of the same gene. Adding to the confusion was the fact that most strains produce both CBD and THC despite breeders’ efforts to grow hemp varieties free from the mind-altering THC for users looking to avoid it.
The chromosome map now clearly shows that two distinct genes are at play, which should make it possible to separate them during breeding to grow plants without THC.
Some psychoactive effects in medical strains could be coming from CBC, a lesser-known cannabinoid that has unusual pharmacology including anti-inflammatory properties. The discovery of the gene responsible for CBC synthesis will make it possible for breeders to tailor its content in future varieties.
“Mainstream science has still not done enough because of research restrictions,” says Dr. Page, of UBC and Chief Scientific Officer at Aurora, one of Canada’s largest producers of medical cannabis. “Legalization and looming ease of research regulation really provide for opportunities for more research to be done. And Canada is leading the way.”
The study was funded by research grants from the Canadian Institutes of Health and Research.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.